GW Pharmaceuticals Plc ADS (GWPH)

[OBhands]

New Frontier Data PR on medical cannabis. GLTA

NEW YORK , June 15, 2017 /PRNewswire/ --
According to a report by New Frontier Data, medical cannabis sales in 2017 are forecast to grow to $5.3 billion, which is 67% of total cannabis sales. The report projects that by 2025, medical sales in current legal states are forecast to grow to $13.2 billion, which will account for 55% of total cannabis sales. Adult use sales in 2017 are forecast to reach $2.6 billion, or rising to $10.9 billion by 2025. With visibility into the spending and consumption habits of cannabis consumers nationally, New Frontier Data has found that medical patient spending is outpacing adult-use consumer spending by a factor of three. In 2016 alone, adult-use consumers shopped once every 14 days and spent $49 per transaction; medical consumers, by contrast, shop once every 10 days and outspend the adult-use customer by more than three-to-one; spending $136 per transaction. Players Network (OTC: PNTV), GW Pharmaceuticals plc (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Insys Therapeutics Inc. (NASDAQ: INSY)
Data shows that cannabis stocks significantly outperformed major indexes in 2016, which is a result of speculative investment based on anticipated expansion of new legal markets. New Frontier reported that the Viridian Cannabis Stock Index gained 236.1% while outperforming such mainstream indexes as the Russell 2000 (up 19.5%), the Dow Jones Industrial Average (up 13.4%), the S&P 500 (up 9.5%), and the Nasdaq composite (up 7.5%). Examining the underlying sectors in the cannabis markets reveals particularly strong growth throughout 2016, both in businesses that touch the plant and in ancillary businesses. Consulting services have also seen strong growth as investors and businesses continually seek advice about how to navigate cannabis regulatory environments, to establish business operations, to shape regulatory policy, and to influence political support.
Players Network (OTCQB: PNTV) earlier today announced that, "it is strengthening its corporate governance, naming Nevada Assistant Controller Geoffrey Lawrence as the company's Chief Financial Officer and Chief Compliance Officer, effective July 1, 2017 .

https://www.networknewswire.com/news-article/

[fung_derf]

It is not done consolidating yet. You still have time

[kabboki]

You did call it.. I'm a novice so it's hard to know when to actually scoop up shares obviously I would have like to get around that 92 but it only touched that area for a short time. Then on its way back up 94-96 (is the drop over I questioned. Now 100 makes me feel like I left some on the table but I see it back at 120s soon

[fung_derf]

Dang! Did I pretty much call a bottom? Still not out of the woods yet but not going below $92.65 this week would be a good sign.

[@realToothFairy]

That was several months ago. Too late now.

[buby89]

I might buy once it gets into the $80s

[SBPartners]

Has Canopy and GWPH finally found a bottom? https://technical420.com/cannabis-article/betting-biotech-has-gw-pharma-found-bottom

[buby89]

I'm going to wait. I think this is going lower a bit more.

[erdos47]

I would add some, just haven't decided - i already have a good position but want to maximize it before the next news break. you know how this jumps up on good news.

[fung_derf]

You mean add?
Actually support has moved up now to $94.01. I would wait to make sure it held support first, so might end up buying it around here (currently $97.24) but prefer to catch it after the rebound has been affirmed.

[erdos47]

Are you going to wait for $92 or just buy in here?

[fung_derf]

Screw Cramer! I told you it was going to $92.

[Eagleize]

Cramer tried to tell y'all. Just let it crash. Will be there to buy in the teens.

[MD-420]

He probably sold out of his trust and trying to get back in it cheaper. He's most definitely not airways right.

[erdos47]

I am surprised that Cramer warned against GWPH. He was all behind it just a few months ago and nothing has changed since then - he said that in addition to the rare conditions being studied, it was a way to decrease use of opioids and treat addiction. GW responded to Cramer, reminding him that their products are medical and not the same as recreational pot. They are going for FDA approval and conducting legit scientific research. Cramer isn't always right in his off-the-cuff remarks.

[Cbdpotential]

If I could..
I would ad
Jmho

[Beerworld]

That's what I thought but doing the opposite.

[Eagleize]

Huge sell off coming. Cramer has spoken.

[fung_derf]

Well there ya go. Same results, different paths to get there

[erdos47]

so will I

[fung_derf]

Quite the contrary. I will add when it gets down to around $93 if I feel it can hold the support.

[erdos47]

so you are going to sell because your chart says this drops to 92? fine with me. I'm just saying that if any drug company has a drug approved for medical use, the share price will go up.

[fung_derf]

If you say so. I'm just reading the charts. All that fundamental assumption hooplah means little to me.

[erdos47]

Strategy here depends on whether you think that large investors are bailing out or is the Cantor Fitz analyst right with a price target of 208 and the prs from the company about clinical trials and submission to FDA for approval are true. If the latter, it won't matter if you buy at 98 or 110 - and if you hold through this dip.

[fung_derf]

Support at $92.82 currently

[MrTrader129]

Whoa, what is goin on here?

[Lavatime]

the last line of the study seems to say it all

Nonetheless, CBD is a safe and effective treatment of refractory epilepsy in patients receiving CLB treatment.

https://www.ncbi.nlm.nih.gov/pubmed/26114620

[jondoeuk]

Any truth in this

$GWPH Why continue to hide key drug-drug interaction data from doctors, patients & investors even in NEJM paper?https://t.co/Ke02E0cVK1

— Andy Biotech (@AndyBiotech) May 25, 2017

[fung_derf]

Stock needs to get above $110 to give a very positive breakout signal.

[erdos47]

NEWS: results of study -successful reduction of seizures- after hours jump in pps- GOING UP FROM HERE. ANALYST PRICE TARGET $208. wheeeeeeee

[richclaire2020]

very true and they will keep dropping until 2018 gltu

[newmedman]

it's not so much phony as it is not real.

somewhere along the line we managed to turn willow bark into aspirin but made cannabis into a dandelion.

They all want to synthesize, homogenize and un- recognize a pot plant.

Some of us will not let them get away with it.

[@realToothFairy]

GW is doing good work, not selling phony CBD like so many scam stocks.
It's too bad that GW has attracted penny stock investors and their gimme gimme mentality.
GW is a solid investment worth holding on to.

[badbadbad]

NICE

[newmedman]

Not really interested in synthetic cannabinoids. I think that the work GW is doing with the raw plant is much more important.

If it weren't for the growers no one would have been able to synthesize the compunds in this wonderful plant.

Keep your synthetic drugs, I'll stick with Mother Nature.

[djmurdock]

I'm heavily invested in $zy#e, which is targeting the same problem and possibly a better delivery system. And a much smaller market cap.

I'll be back in GW after summer.

[newmedman]

bummer. Just remember the small child who suffers from seizures every day.

and a way to fix that.

[djmurdock]

I just sold all mine (was riding free) and will buy back in later. Not seeing any upcoming catalysts and the downtrend is getting ugly.

Great long term, but could dip a lot more before substantial news.

[fung_derf]

I see support around $92. Guess I should have dumped to buy back in later.

[whatarush12]

Still doesn't look like support yet? Any thoughts here??

[realtynj]

Can someone tell me the SS and market cap?

[fung_derf]

I don't see any support at $105

[erdos47]

i admit i worried about how this would open today - don't know what investors wanted from earnings because it costs to research, gain approvals, expand production capability and hire sales reps. $105 is holding so patience will eventually pay off. up from here!

[erdos47]

bounced off 105. up from here

[fung_derf]

Dang it! It broke support levels! Next one around $92 currently

[erdos47]

Cantor Fitz analyst came out with optimistic outlook and 208 price target, so I would say to stick with this real company and this is a buying opportunity. No need to go after penny stocks, and why mix CBD with wine???? sounds like red bull and vodka.

[JohnCM]

Yes, I bought the IPO at $9.00

No, I did not hold it.

[erdos47]

Anyone getting a read on the conference call? Dry technical presentation but the questions are interesting. 45 acre glass house being built - so they plan for increased production, but they had greater loss per share than expected - how will investors take this tomorrow?

[cover2]

Not much happening with MJ stocks these days.

[fung_derf]

OK. Then quitcher complaining